Sorrento Therapeutics Inc SRNE is trading higher Thursday after the company received EUA approval and a product import license from COFEPRIS for its rapid COVID-19 test, COVI-STIX.
COVI-STIX is a 15-minute rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients.
Sorrento Therapeutics is establishing a local “Sorrento Mexico Ltd” subsidiary to manage commercial operations in Mexico. The company will commercially launch the COVI-STIX test in Mexico with the first shipments expected to be delivered in July.
See Also: Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch
Sorrento Therapeutics is a clinical stage biopharmaceutical company focused on developing new therapies to treat cancers and COVID-19.
Price Action: Sorrento Therapeutics has traded as high as $19.39 and as low as $4.84 over a 52-week period.
At last check Thursday, the stock was up 8.68% at $9.82.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
